Valuation: Imugene Limited

Market Cap 21.55M 15.13M 13.28M 12.54M 11.43M 21.39M 1.45B 150M 58.13M 741M 56.82M 55.59M 2.38B P/E 2027 *
-0.56x
P/E 2028 * -0.74x
Enterprise Value 20.55M 14.43M 12.66M 11.96M 10.9M 20.4M 1.38B 143M 55.43M 707M 54.18M 53.01M 2.27B EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
96.9%
Yield 2027 *
-
Yield 2028 * -
1 week-6.38%
Current month-35.29%
1 month-38.03%
3 months-54.64%
6 months-68.57%
Current year-87.95%
1 week 0.04
Extreme 0.042
0.05
1 month 0.04
Extreme 0.042
0.07
Current year 0.04
Extreme 0.042
0.41
1 year 0.04
Extreme 0.042
0.46
3 years 0.04
Extreme 0.042
5.1
5 years 0.04
Extreme 0.042
21.25
10 years 0.04
Extreme 0.042
21.25
Manager TitleAgeSince
Director of Finance/CFO - 2025-03-03
Chief Tech/Sci/R&D Officer - 2023-08-31
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Chairman 70 2012-10-30
Director/Board Member 66 2019-04-22
Director/Board Member 61 2022-09-06
Date Insider Type Main position Quantity % Market Cap. Importance
12/19/25 Free

Director

14,706 0.0047%
12/19/25 Free

Director

29,411 0.0093%
12/19/25 Exercice

Director

14,706 0.0047%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-6.38%-83.70%-97.36% 15.13M
-0.14%+4.33%+9.00%+31.64% 47.97B
-1.69%+1.48%+50.57%+34.53% 44.5B
+2.56%+7.34%+366.69%+608.26% 43.93B
+0.24%+2.85%+10.67%+94.47% 41.03B
-0.62%-1.11%+4.65%+48.91% 29.85B
-0.28%+1.07%+24.58%+155.58% 17.27B
+3.37%+9.21%+8.32% - 15.34B
-0.46%+1.20%+26.90%+42.21% 15.3B
-2.21%-4.70% - - 14.82B
Average +0.08%+1.48%+46.41%+114.78% 27B
Weighted average by Cap. +0.11%+2.86%+79.66%+160.26%

Financials

2027 *2028 *
Net sales - -
Net income -42.79M -30.05M -26.37M -24.9M -22.69M -42.48M -2.88B -298M -115M -1.47B -113M -110M -4.73B -33.44M -23.49M -20.61M -19.46M -17.74M -33.2M -2.25B -233M -90.21M -1.15B -88.18M -86.27M -3.7B
Net Debt -1M -702K -616K -582K -530K -993K -67.31M -6.96M -2.7M -34.39M -2.64M -2.58M -111M -
Logo Imugene Limited
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
Employees
14
Date Price Change Volume
26-09-25 A$0.0440 0.00% 2,229,255
26-09-24 A$0.0440 0.00% 2,162,405
26-09-23 A$0.0440 -6.38% 3,479,990
26-09-22 A$0.0470 0.00% 2,093,399
26-09-21 A$0.0470 0.00% 2,229,871
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0440AUD
Average target price
0.3067AUD
Spread / Average Target
+596.98%

Quarterly revenue - Rate of surprise